CNS International Growth, Ad/Promo Cuts Key Strategies For FY 2003
This article was originally published in The Tan Sheet
Executive Summary
CNS aims to increase international sales by up to 20% in 2002 as part of its strategy to boost revenue and continue recent earnings gains
You may also be interested in...
Sales & Earnings In Brief
Perrigo Q2 results: Private labeler tells analysts Jan. 24 it will take a $1.9 mil. charge in fiscal second quarter ended Dec. 29 due to Kmart's bankruptcy filing. Although shipments to struggling retailer declined in past two months, President and CEO David Gibbons says he expects regular shipping levels to return in February. Company also sold its LaVergne, Tenn. distribution center for $14.2 mil. in Q2. Perrigo three-month cough/cold sales rose 16%, while GI revenues jumped 12% as a result of famotidine 10 mg (Pepcid AC) uptake. Net sales rose 20.6% to $228.7 mil. in Q2, net income jumped over 1,900% to $16.6 mil. Percentages, particularly earnings, reflect year-ago charges due to Perrigo's recall of PPA products...
CNS Breathe Right Sales, FiberChoice Cuts Produce "Return To Profitability"
CNS expects FiberChoice to become a $30 mil. product in the long term, which would equate to about 10% of the fiber category, the company said.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC